Clinical study of sitafloxacin in treatment of cervicitis with <I>Chlamydia trachomatis</I>

• Matsuda Seiji

  Japanese Foundation of Sexual Health Medicine

• Noguchi Masayoshi

  Department of Obstetrics and Gynecology, Aichi Medical University

• Yasuda Jinsuke

  Department of Obstetrics and Gynecology, Matsushita Memorial Hospital

• Hori Seiji

  Department of Pharmacology, Jikei University School of Medicine

Bibliographic Information

Other Title

• <I>Chlamydia trachomatis</I>による子宮頸管炎を対象としたsitafloxacinの一般臨床試験

Abstract

The clinical efficacy and safety of sitafloxacin (STFX), a new quinolone compound, were evaluated in patients with cervicitis with Chlamydia trachomatis. STFX was administered orally at 50 mg twice a day for 7 days.<BR>Overall clinical efficacy was 97.5%(39/40) in cervicitis. Eradication in microbiological outcome for C. trachomatis was 97.5%(39/40). Cure at the end of treatment was 32.5%(13/40) and at 1-2 weeks after the end of treatment was 47.5%(19/40).<BR>Adverse reactions occurred in 23.3%(10/43) of cases evaluable for safety, the most common being diarrhoea at an incidence of 9.3%(4/43). All symptoms were mild or moderate.<BR>Results suggest that STFX is effective and safe in the treatment of cervicitis with C. trachomatis.

Journal

• Japanese Journal of Chemotherapy

  Japanese Journal of Chemotherapy 56 (Supplement1), 139-145, 2008

  Japanese Society of Chemotherapy

Keywords

• sitafloxacin
• cervicitis
• Chlamydia trachomatis
• clinical trial

Details

• CRID: 1390001206288105856
• NII Article ID: 10021192912
• NII Article ID: 130004102780
• NII Book ID: AN10472127
• DOI: 10.11250/chemotherapy1995.56.supplement1_139
• ISSN: 18845886
• ISSN: 13407007
• Web Site: https://search.jamas.or.jp/link/ui/2008207517
• Text Lang: ja
• Data Source:
  • JaLC
  • CiNii Articles
• Abstract License Flag: Disallowed